Trial · NCT01453049
Results by group150
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 150
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Fasting Proinsulin and Insulin at Week 24/Early Withdrawal (EW) | Rosiglitazone+Glimepiride FDC | Insulin; n=15, 19 | 9.3 | Standard Deviation 32.27 | Picomoles per liter (pmol/L) |
| Change From Baseline in Fasting Proinsulin and Insulin at Week 24/Early Withdrawal (EW) | Glimepiride | Insulin; n=15, 19 | 24.9 | Standard Deviation 40.03 | Picomoles per liter (pmol/L) |
| Change From Baseline in Homeostasis Model Assessment Sensitivity (HOMA-S) at Week 24/EW | Rosiglitazone+Glimepiride FDC | 1.7248 | Standard Deviation 7.2543 | Ratio: FI*FG (num.); 22.5 (denom.) | |
| Change From Baseline in Homeostasis Model Assessment Sensitivity (HOMA-S) at Week 24/EW | Glimepiride | -2.9173 | Standard Deviation 4.5282 | Ratio: FI*FG (num.); 22.5 (denom.) | |
| Change From Baseline in Homeostasis Model Assessment Beta-cell Function (HOMA-B) at Week 24/EW | Rosiglitazone+Glimepiride FDC | 1.0494 | Standard Deviation 1.3229 | Ratio: 20*FI (num.); FG-3.5 (denom.) | |
| Change From Baseline in Homeostasis Model Assessment Beta-cell Function (HOMA-B) at Week 24/EW | Glimepiride | 1.0108 | Standard Deviation 1.1724 | Ratio: 20*FI (num.); FG-3.5 (denom.) | |
| Number of Participants at Various Dose Levels at Week 24/EW | Rosiglitazone+Glimepiride FDC | Dose Level 1 | 16 | participants | |
| Number of Participants at Various Dose Levels at Week 24/EW | Glimepiride | Dose Level 1 | 7 | participants | |
| Number of Participants at Various Dose Levels at Week 24/EW | Rosiglitazone+Glimepiride FDC | Dose Level 2 | 8 | participants | |
| Number of Participants at Various Dose Levels at Week 24/EW | Glimepiride | Dose Level 2 | 18 | participants | |
| Number of Participants at Various Dose Levels at Week 24/EW | Rosiglitazone+Glimepiride FDC | Dose Level 3 | 10 | participants | |
| Number of Participants at Various Dose Levels at Week 24/EW | Glimepiride | Dose Level 3 | 13 | participants | |
| Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW | Rosiglitazone+Glimepiride FDC | TC; n=35, 36 | 0.146 | Standard Deviation 0.6736 | mmol/L |
| Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW | Glimepiride | TC; n=35, 36 | 0.186 | Standard Deviation 0.8849 | mmol/L |
| Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW | Rosiglitazone+Glimepiride FDC | HDL-C; n=35, 34 | -0.003 | Standard Deviation 0.2141 | mmol/L |
| Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW | Glimepiride | HDL-C; n=35, 34 | 0.091 | Standard Deviation 0.1797 | mmol/L |
| Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW | Rosiglitazone+Glimepiride FDC | LDL-C; n=34, 31 | 0.002 | Standard Deviation 0.5598 | mmol/L |
| Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW | Glimepiride | LDL-C; n=34, 31 | 0.067 | Standard Deviation 0.6075 | mmol/L |
| Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW | Rosiglitazone+Glimepiride FDC | TG; n=35, 37 | 0.344 | Standard Deviation 1.0933 | mmol/L |
| Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW | Glimepiride | TG; n=35, 37 | 0.056 | Standard Deviation 1.5312 | mmol/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01453049/results?page=2